One of AstraZeneca Plc’s top-selling drugs Farxiga, a diabetes treatment, is beneficial to a wider pool of patients than previously indicated, a study shows, bolstering the product’s blockbuster potential.
Read More
© Newspaper Theme by tagDiv | All rights reserved.